A carregar...
Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection
We studied the clinical and economic impact of a protocol encouraging the use of fidaxomicin as a first-line drug for treatment of Clostridium difficile infection (CDI) in patients hospitalized during a 2-year period. This study evaluated patients who received oral vancomycin or fidaxomicin for the...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4604404/ https://ncbi.nlm.nih.gov/pubmed/26324268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00939-15 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|